Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI3003 vs Investigator's Choice in Relapsed or Refractory Multiple Myeloma
NCT07623798Phase 3Recruiting
- Sponsor
- Innovent Biologics
- Start
- Jun 2026
- Primary completion
- May 2029
- Countries
- 1
01
Overview
A Phase 3 trial of IBI3003 in multiple myeloma (MM), sponsored by Innovent Biologics. Started Jun 2026; status: recruiting.
02
Drugs
IBI3003
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07623798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07623798.